INTRODUCTION {#sec1-1}
============

The Epidermal growth factor receptor (EGFR) is over expressed in various solid malignancies including non small cell lung cancer (NSCLC). Hence EGFR inhibitors - gefitinib and erlotinib are used in advanced NSCLC. However, they are associated with a dermatologic side effects, which can occasionally be responsible for discontinuation of the EGFR inhibitors. Hence, we report a case of metastatic adenocarcinoma of lung who developed skin ulceration with gefitinib and responded to interruption of the drug and early intervention.

CASE REPORT {#sec1-2}
===========

The present case report is about a 50-year-old female patient who had been diagnosed as having lung adenocarcinoma with multiple bone metastases was initiated on gefitinib therapy at an oral dose of 250 mg/d. She had a positive epidermal growth factor receptor (EGFR) mutation status. After 2 weeks of initiating therapy, the patient presented with ulcer over the palm \[[Figure 1](#F1){ref-type="fig"}\]. The ulcers improved with stopping gefitinib for 2 weeks and also with the addition of topical steroids and antibiotics.

![Ulcer over the palm with granulation tissue in a woman on gefitinib](IJMPO-35-109-g001){#F1}

DISCUSSION {#sec1-3}
==========

Non-small-cell lung cancer (NSCLC) with sensitive mutations of the EGFR is highly responsive to gefitinib. Gefitinib is a small molecule tyrosine kinase inhibitor (TKI) of EGFR.\[[@ref1]\] Since 2004, it was clear that a substantial proportion of NSCLC obtaining objective response when treated with gefitinib harboring activating mutations in the EGFR gene.\[[@ref2]\] The occurrence of skin disorders (dry skin and acneiform rash) is explained by the fact that EGFR is also expressed in the basal layer of the skin; inhibition of the receptor will disturb normal biology and result in skin rash.\[[@ref3][@ref4]\] Skin rash is notorious as an adverse event of EGFR-TKI and is noted in up to two-thirds of patients receiving any of these agents although severe in only 5-10% who can develop pyogenic granuloma like lesions. Very rarely the cutaneous inflammation is so pronounced that skin necrosis with black eschar formation and ulceration is seen.\[[@ref5]\] The cutaneous side-effects are treated with topical steroids and antibiotics with interruption of treatment for 2-4 weeks as in our case. Our patient responded to the above treatment with break in treatment for 2 weeks.\[[@ref6]\]
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